Status:
COMPLETED
Effects of Gastric Bypass on Blood Levels of Duloxetine
Lead Sponsor:
Neuropsychiatric Research Institute, Fargo, North Dakota
Collaborating Sponsors:
University of North Dakota
Eli Lilly and Company
Conditions:
Bariatric Surgery
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
This study aims to determine the difference, if any, in the pharmacokinetics of duloxetine between patients who are nine to fifteen months post Roux-en-Y Bariatric Surgery and control subjects matched...
Eligibility Criteria
Inclusion
- Male or female subjects between the ages of 18 and 60 years.
- Subjects must be of good general health by history and physical exam.
- Ten experimental subjects 9 to 15 months post bariatric surgery (Roux-en-Y procedure), no BMI requirement.
- Ten normal control subjects who have met the inclusion criteria and have not received bariatric surgery and who are matched to the surgery subjects according to body mass index, age and sex.
- Women of child bearing potential must be practicing an accepted method of birth control (barrier method or oral contraceptive) and have a negative pregnancy test at baseline.
- No contraindications to receiving a single capsule of 60 mg of duloxetine
Exclusion
- Allergy to duloxetine or any of its constituents.
- Candidates who are pregnant or nursing
- Candidates currently receiving any antidepressant.
- Candidates that are determined to be poor metabolizers for CYP2D6
- Subjects who smoke or use any nicotine products
- Candidates currently receiving a medication that interacts with duloxetine.
- Candidates experiencing clinically significant, unstable neurological, hepatic, renal or cardiovascular disease.
- Candidates experiencing or with a history of vomiting or diarrhea associated with bariatric surgery
- Candidates currently or with a past history of meeting DSM-IV diagnostic criteria for schizophrenia, schizoaffective disorder, bipolar disorder.
- Candidates who have participated in an investigational drug study in past 30 days.
- Candidates who meet DSM-IV diagnostic criteria for drug/alcohol abuse or dependency or who have a history of drug/alcohol abuse or dependency.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00989157
Start Date
September 1 2009
End Date
November 1 2012
Last Update
August 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuropsychiatric Research Institute
Fargo, North Dakota, United States, 58103